Comparative risks of venous thromboembolism among users of oral contraceptives containing drospirenone and levonorgestrel

J Fam Plann Reprod Health Care. 2011 Jul;37(3):132-5. doi: 10.1136/jfprhc-2011-14524. Epub 2011 Jun 9.

Authors

Klaas Heinemann¹, Lothar A J Heinemann

Affiliation

¹ ZEG - Berlin, Berlin, Germany. k.heinemann@zeg-berlin.de

PMID: 21659330
DOI: 10.1136/jfprhc-2011-14524

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Androstenes / administration & dosage
Androstenes / adverse effects*
Contraceptives, Oral / adverse effects*
Contraceptives, Oral, Synthetic / adverse effects
Female
Humans
Levonorgestrel / administration & dosage
Levonorgestrel / adverse effects*
Mineralocorticoid Receptor Antagonists / administration & dosage
Mineralocorticoid Receptor Antagonists / adverse effects*
Risk Assessment
Venous Thromboembolism / chemically induced*

Substances

Androstenes
Contraceptives, Oral
Contraceptives, Oral, Synthetic
Mineralocorticoid Receptor Antagonists
Levonorgestrel
drospirenone